Date: 22nd June, 2017

To,
The Manager,
Listing Department
National Stock Exchange of India Ltd
'Exchange Plaza'
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Dear Sir/Madam,

Sub: Alembic Pharmaceuticals Limited receives USFDA Approval for Amantadine Hydrochloride Capsules, USP

With reference to the captioned subject, this is to inform the exchange that the Company has received US Food & Drug Administration (USFDA) approval for Amantadine Hydrochloride Capsules, USP. Please find enclosed herewith our press release.

We request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Alembic Pharmaceuticals Limited

R. K. Baheti
Director – Finance & CFO

Encl.: A/a.

Alembic
Touching Lives over 100 years

PRESS RELEASE

22nd June, 2017, Vadodara, India

Alembic Pharmaceuticals receives USFDA Approval for Amantadine Hydrochloride Capsules, USP

Alembic Pharmaceuticals Limited today announced that the company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Amantadine Hydrochloride Capsules, USP, 100mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Symmetrel® Capsules, 100mg, of Endo Pharmaceuticals Inc. Amantadine Hydrochloride Capsules, USP are indicated for the prophylaxis and treatment of signs and symptoms of infection caused by various strains of influenza A virus. Amantadine Hydrochloride Capsules, USP are also indicated in the treatment of parkinsonism and drug-induced extrapyramidal reactions.

Amantadine Hydrochloride Capsules have an estimated market size of US$ 37 million for twelve months ending December 2016 according to IMS.

Alembic now has a total of 58 ANDA approvals (52 final approvals and 6 tentative approvals) from USFDA.

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the USFDA. Alembic is one of the leaders in branded generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at http://www.alembicpharmaceuticals.com/; (Reuters: ALEM.NS) (Bloomberg: ALPM) (NSE: APLLTD) (BSE: 533573)

For more information contact:

Ajay Kumar Desai Phone: +91 22 - 306 11681 Email: ajay.desai@alembic.co.in	Mitanshu Shah Phone: +91 265 - 3007630 Email: mitanshu.shah@alembic.co.in

ALEMBIC PHARMACEUTICALS LIMITED VADODARA 390 003.